|
Objective: To observe the L-carnitine on maintenance hemodialysis (MHD) patients with micro-inflammatory state, and explore the L-carnitine on MHD patients microinflammatory mechanism. Methods: Our hospital routine blood purification center hemodialysis treatment time in six months, and more than 43 patients were randomly divided into control group and treatment group 21 cases, 22 cases of the control group at the end of each dialysis treatment from Dialysis venous injection of saline 20m1; treatment groups at the end of each dialysis treatment from dialysis access venous injection 2.0g L-carnitine plus saline to 20ml. Two groups in gender, age, primary disease, etc. Statistically, there was no significant difference (P gt; 0.05), observation time was 3 months. Statistical two dialysis during treatment the number of cases of complications and detect micro-inflammatory markers before and after treatment: serum high sensitivity c-reactive protein (hs-CRP), interleukin -6 (IL-6), tumor necrosis factor -α (TNF-α) levels involved in inflammation and nuclear factor kappaB (NF-κB) activity. Results: 1. Two groups before treatment compared to baseline: inflammatory cytokines showed no significant difference; 2 compared before and after treatment: After treatment, CRP, IL-6, TNF-α compared with before treatment were significantly different (P lt ; 0.05); control group CRP, IL-6, TNF-α before and after treatment, the difference was not statistically significant (P gt; 0.05) 3. treatment group compared with the control group: the treatment group in reducing CRP, IL-6, TNF -α are significantly better than the control group, the difference was statistically significant (P lt; 0.05) 4.NF-κB activity levels and CRP, IL-6, TNF-α values ??showed a positive correlation coefficient was 0.71 (P lt; 0.05), 0.56 (P lt; 0.05), 0.67 (P lt; 0.05). 5 in the treatment group compared with the control group had to compare the number of dialysis patients with complications: the treatment group appear weak one case, two cases of fatigue, muscle cramps one case, hypotension two cases; control group appear weak in 2 cases, 3 cases of fatigue, muscle cramps three cases, hypotension four cases, the treatment group, the clinical symptoms improved significantly better than the control group, the difference was not statistically significant (P lt; 0.05). Conclusions: 1. L-carnitine can reduce inflammatory markers in MHD patients had improved micro-inflammation; 2. L-carnitine can inhibit the activity of NF-κB plays a role in the treatment of inflammation. 3 MHD L-carnitine can reduce the incidence of complications of dialysis patients and improve their quality of life. 4 L-carnitine fewer adverse reactions, drug safety, convenience, improved micro-inflammatory state MHD patients, it is worth further exploration.
|